EML4 and non-small cell lung carcinoma: Preclinical studies have shown that lorlatinib could inhibit cell proliferation and induce apoptosis in NSCLC cells that harbor the EML4-ALK fusion and the V1180L mutation through inhibition of AKT phosphorylation (18).